<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680197</article-id><article-id pub-id-type="doi">10.3390/vaccines12121396</article-id><article-id pub-id-type="publisher-id">vaccines-12-01396</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Receptor Binding Domain-Specific B Cell Memory Responses Among Individuals Vaccinated Against SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0000-5066-1833</contrib-id><name><surname>Athavale</surname><given-names>Atharv</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-0950-3228</contrib-id><name><surname>Gaur</surname><given-names>Anmol</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-2590-9300</contrib-id><name><surname>Ahmed</surname><given-names>Nafees</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0000-0301-9303</contrib-id><name><surname>Subramaniam</surname><given-names>Adarsh</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dandotiya</surname><given-names>Jyotsna</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Raj</surname><given-names>Sneha</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Upadhyay</surname><given-names>Santosh Kumar</given-names></name><xref rid="af2-vaccines-12-01396" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Samal</surname><given-names>Sweety</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Pandey</surname><given-names>Anil Kumar</given-names></name><xref rid="af3-vaccines-12-01396" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8008-3904</contrib-id><name><surname>Rai</surname><given-names>Ramesh Chandra</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01396" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2563-1971</contrib-id><name><surname>Awasthi</surname><given-names>Amit</given-names></name><xref rid="af1-vaccines-12-01396" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01396" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Georgopoulos</surname><given-names>Apostolos P.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Pincus</surname><given-names>Seth</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01396"><label>1</label>BRIC-Translational Health Science and Technology Institute, Faridabad 21001, India; <email>atharv1athavale@gmail.com</email> (A.A.); <email>anmolgaur454@gmail.com</email> (A.G.); <email>nafeesahmed23197@gmail.com</email> (N.A.); <email>adarsh.n@thsti.res.in</email> (A.S.); <email>jyotsna@thsti.res.in</email> (J.D.); <email>sneharaj@thsti.res.in</email> (S.R.); <email>sweety.samal@thsti.res.in</email> (S.S.)</aff><aff id="af2-vaccines-12-01396"><label>2</label>Department of Biotechnology, Kumaun University, Nainital 263001, India; <email>upadhyaysk97@gmail.com</email></aff><aff id="af3-vaccines-12-01396"><label>3</label>ESIC Medical College and Hospital, Faridabad 121012, India; <email>drpandeyak@yahoo.co.in</email></aff><author-notes><corresp id="c1-vaccines-12-01396"><label>*</label>Correspondence: <email>rairamesh@gmail.com</email> or <email>rairamesh@thsti.res.in</email> (R.C.R.); <email>aawasthi@thsti.res.in</email> (A.A.); Tel.: +91-1292876218 (R.C.R.); +91-1292876482 (A.A.)</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1396</elocation-id><history><date date-type="received"><day>19</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>14</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: The COVID-19 pandemic prompted unprecedented vaccine development efforts against SARS-CoV-2. India, which was one of the countries most impacted by COVID-19, developed its indigenous vaccine in addition to utilizing the ones developed by other countries. While antibody levels and neutralizing antibody titres are considered initial correlates of immune protection, long-term protection from the pathogen relies on memory B and T cells and their recall responses. In this regard, global research has primarily focused on mRNA-based vaccines. The studies on immune memory response, particularly B cell memory response induced by the vaccines given to Indians, remain relatively obscure. <bold>Methods</bold>: We assessed Receptor Binding Domain-specific memory B cells in the peripheral circulation and their ability to secrete antigen-specific antibodies among Indians vaccinated with Covaxin (BBV152), Covishield (AZD1222), Corbevax (BECOV2D), and Sputnik Light, as well as unvaccinated individuals. <bold>Results</bold>: Corbevax and Sputnik Light conferred better antibody-secreting cell (ASC) responses over time compared to other groups. <bold>Conclusions</bold>: These findings contribute to our understanding of vaccine-induced immune memory in the Indian population; providing insights that could inform future vaccine strategies.</p></abstract><kwd-group><kwd>receptor-binding domain (RBD)</kwd><kwd>memory B cell (MBC)</kwd><kwd>antibody-secreting cell (ASC)</kwd><kwd>severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</kwd><kwd>coronavirus disease 2019 (COVID-19)</kwd></kwd-group><funding-group><award-group><funding-source>BRIC-THSTI, Faridabad</funding-source><award-id>no. P314</award-id></award-group><funding-statement>This research and the APC were funded by BRIC-THSTI, Faridabad (Intramural project no. P314).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01396"><title>1. Introduction</title><p>Vaccines are used to protect people from various diseases and to limit their transmission to a larger population. Since the inception of vaccination in 1796, there have been tremendous advancements in the field of vaccinology. From early whole-pathogen-inactivated vaccines to modern mRNA vaccines, the field has shown great progress, reaching a crucial turning point during the recent COVID-19 pandemic [<xref rid="B1-vaccines-12-01396" ref-type="bibr">1</xref>]. While vaccines against SARS-CoV-2 have proven their effectiveness in mitigating severe symptoms and reducing hospitalization, the cellular memory responses they induce remain largely uncharacterized [<xref rid="B2-vaccines-12-01396" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-12-01396" ref-type="bibr">3</xref>]. Antibody responses, on the other hand, have been studied extensively. Notably, in addition to IgG, both IgA and IgM are capable of neutralizing viral antigens [<xref rid="B4-vaccines-12-01396" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01396" ref-type="bibr">5</xref>]. Besides antibodies, the generation and maintenance of immune memory is an important component of long-term protection, which involves T and B memory cells [<xref rid="B6-vaccines-12-01396" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01396" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01396" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-12-01396" ref-type="bibr">9</xref>]. Cytotoxic CD8+ T cells eliminate the cells infected with an intracellular pathogen such as a virus, while CD4+ T cells generate a cytokine milieu conducive for B and T cell maturation and memory development [<xref rid="B10-vaccines-12-01396" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-01396" ref-type="bibr">11</xref>]. Memory B cells (MBCs) are generated in response to an infection or vaccination and add a further layer of protection [<xref rid="B12-vaccines-12-01396" ref-type="bibr">12</xref>]. B cell affinity maturation occurs in the transient but specialized structures known as &#x02018;germinal centres&#x02019; [<xref rid="B13-vaccines-12-01396" ref-type="bibr">13</xref>]. After a proliferative stage where a B cell clone undergoes somatic hypermutation and antigen-based selection, only those producing high-affinity antibodies survive and differentiate into MBCs [<xref rid="B14-vaccines-12-01396" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01396" ref-type="bibr">15</xref>]. This process continues for several months after vaccination or an infection, resulting in antibodies with improved avidity and neutralization capacity [<xref rid="B8-vaccines-12-01396" ref-type="bibr">8</xref>,<xref rid="B15-vaccines-12-01396" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-12-01396" ref-type="bibr">16</xref>]. The affinity maturation process expands the breadth of recognition with increased affinity of the antibodies, and the generated pool of MBCs is multi-pronged with anticipatory memory potential [<xref rid="B15-vaccines-12-01396" ref-type="bibr">15</xref>].</p><p>A comparative assessment of memory B cell response elicited by different vaccines holds the potential to provide invaluable insights into their relative efficacies in promoting enduring immune memory, thereby facilitating the development of evidence-based vaccination strategies [<xref rid="B17-vaccines-12-01396" ref-type="bibr">17</xref>]. It is also important to assess the level of memory cells present in the peripheral circulation of vaccinees over time as well as their ability to respond to recurrent invasion by the pathogen [<xref rid="B18-vaccines-12-01396" ref-type="bibr">18</xref>]. There are concerns regarding the potential decline in vaccine efficacy, as viruses carrying mutations in key neutralizing antibody epitopes propagate in the community, allowing them to partially or completely evade antibody recognition [<xref rid="B19-vaccines-12-01396" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01396" ref-type="bibr">20</xref>]. There are also reports in certain cases of severe COVID-19, that the affinity maturation of B cells is compromised [<xref rid="B21-vaccines-12-01396" ref-type="bibr">21</xref>]. In India, several COVID-19 vaccines have been administered, including viral vector-based vaccines (Covishield, Sputnik Light, Sputnik V), an inactivated virus-based vaccine (Covaxin), and a protein subunit vaccine (Corbevax) [<xref rid="B22-vaccines-12-01396" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01396" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01396" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01396" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01396" ref-type="bibr">26</xref>]. After the promising results shown by these vaccines, with efficacies ranging from 70.4% to over 90%, their long-term effectiveness and the ability to generate immune memory are the areas of active research [<xref rid="B27-vaccines-12-01396" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-01396" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01396" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-12-01396" ref-type="bibr">30</xref>]. Despite the initial success, waning vaccine protection and breakthrough infections have been observed [<xref rid="B31-vaccines-12-01396" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-12-01396" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-12-01396" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01396" ref-type="bibr">34</xref>]. This is partly linked to SARS-CoV-2&#x02019;s high mutation rate and immune evasion capabilities [<xref rid="B35-vaccines-12-01396" ref-type="bibr">35</xref>]. However, comprehensive data are not available to convincingly explain this immunological insufficiency that leads to pathogen&#x02019;s upsurge with time, particularly in the Indian context.</p><p>The goal of this study was to address this knowledge gap by examining the diverse aspects of the antigen-specific B cell immune response three months after vaccination. Our readouts were based on the receptor-binding domain (RBD) of the spike protein of the SARS-CoV-2 Wuhan strain. It is well-established that the immune response against RBD has been shown to be dominant and correlates well with virus neutralization [<xref rid="B18-vaccines-12-01396" ref-type="bibr">18</xref>,<xref rid="B36-vaccines-12-01396" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-12-01396" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-12-01396" ref-type="bibr">38</xref>]. Our objective was to compare the memory B cell response generated by four vaccines&#x02014;Covaxin (BBV152), Covishield (AZD1222), Corbevax (BECOV2D), and Sputnik Light&#x02014;and the ability of these cells to proliferate and secrete anti-RBD antibodies. We characterized circulating memory B cells using the conventional combination of CD27 and IgD as phenotypic markers [<xref rid="B39-vaccines-12-01396" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-12-01396" ref-type="bibr">40</xref>]. By comparing these diverse vaccines, which differ in their development platforms or dose regimens, we aimed to provide insights into their ability to confer enduring immunity.</p></sec><sec id="sec2-vaccines-12-01396"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-12-01396"><title>2.1. Ethics Statement</title><p>This study was conducted at the BRIC-Translational Health Science and Technology Institute, Faridabad, India. Participant enrolment and sample collection were done at ESIC Medical College and Hospital, Faridabad. Written informed consent was obtained from each of the study participants. This study was approved by the institutional ethics committees of both institutes (ESIC Hospital and Medical College, Faridabad File no. 134 X/11/13/2021- IEC/43 and BRIC-THSTI Faridabad Ref No: THS 1.8.1/(130) dated 27 October 2021).</p></sec><sec id="sec2dot2-vaccines-12-01396"><title>2.2. Participant Details</title><p>Samples were collected from a total of 171 participants, and their age, sample collection date, and vaccination details were recorded. The participants were of the following categories: unvaccinated (35 participants) and vaccinated (Corbevax&#x02014;34, Covaxin&#x02014;33, Covishield&#x02014;40, and Sputnik Light&#x02014;29) (<xref rid="vaccines-12-01396-t001" ref-type="table">Table 1</xref>). The sample collection for this study coincided largely with the Omicron-I (December 2021&#x02013;June 2022) and partially with the Omicron-II (July 2022&#x02013;October 2023) periods.</p></sec><sec id="sec2dot3-vaccines-12-01396"><title>2.3. Inclusion and Exclusion Criteria</title><p>The analysis included participants with ages 18&#x02013;59 years having no documented history of SARS-CoV-2 infection. Eligible individuals were either unvaccinated or had completed a full vaccination course (two doses for BBV152, AZD1222, and BECOV2D; a single dose for Sputnik Light). Participants were excluded if they had obtained a booster vaccine dose prior to specimen collection or had reported a prior infection at the time of enrolment. Pregnant women and people with immunocompromising comorbidities were also excluded from the study.</p></sec><sec id="sec2dot4-vaccines-12-01396"><title>2.4. Blood Collection and Sample Processing</title><p>8 mL of blood was collected from each participant, in Greiner Bio-One tubes (Noida, India, Cat. No. 22-040-134) coated with sodium heparin. Blood samples were processed immediately to isolate plasma and peripheral blood mononuclear cells (PBMCs) using Lymphoprep density gradient centrifugation. Plasma was stored at &#x02212;80 &#x000b0;C, and PBMCs were resuspended in fetal bovine serum (FBS) supplemented with 10% dimethyl sulfoxide (DMSO) and then stored in liquid nitrogen [<xref rid="B16-vaccines-12-01396" ref-type="bibr">16</xref>].</p></sec><sec id="sec2dot5-vaccines-12-01396"><title>2.5. Indirect Anti-RBD IgG ELISA</title><p>96-well Maxisorp plates (Thermo Fisher Scientific, Roskilde, Denmark-Cat No. 442404) were coated with 100 &#x000b5;L of RBD protein (2 &#x000b5;g/mL in PBS) per well and incubated overnight at 4 &#x000b0;C. Plates were washed with PBST (PBS + 0.1% Tween 20) and blocked for two hours at 37 &#x000b0;C with a block buffer (PBST + 3% skimmed milk). After incubation, the block buffer was discarded, and 100 &#x000b5;L per well of the diluted plasma samples were added in duplicates. Plasma samples were diluted in PBST + 3% skimmed milk at a ratio of 1:150. The plate was incubated for 30 min at 37 &#x000b0;C and then was washed with PBST. Further, 100 &#x000b5;L of secondary antibodies was added per well [Goat anti-human IgA HRP-conjugated (Southern Biotech, Birmingham, AL, USA, 2050-05; 1:5000 dilution), goat anti-human IgG HRP-conjugated (Jackson Immunoresearch, West Grove, PA, USA, 109-035-088; 1:10,000 dilution), and goat anti-human IgM HRP-conjugated (Jackson Immunoresearch 109-035-129; 1:10,000 dilution)]. The plate was incubated for 30 min at room temperature and then washed with PBST. TMB substrate was added in the dark and was incubated for 3 min. The reaction was stopped with 1 N H<sub>2</sub>SO<sub>4</sub> before measuring the optical densities at 450 nm using a microplate reader [<xref rid="B41-vaccines-12-01396" ref-type="bibr">41</xref>].</p></sec><sec id="sec2dot6-vaccines-12-01396"><title>2.6. Expression and Purification of the RBD Protein of SARS-CoV-2 (Wuhan Strain-Hu-1)</title><p>The following reagent was contributed by David Veesler for distribution through BEI Resources, NIAID, NIH: Vector pcDNA3.1(-) containing the SARS-related coronavirus 2, Wuhan-Hu-1 spike glycoprotein receptor-binding domain (RBD), and NR-52422as, as mentioned previously [<xref rid="B42-vaccines-12-01396" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-12-01396" ref-type="bibr">43</xref>]. The recombinant his-tagged SARS-CoV-2 ancestral Wu-RBD protein was expressed in transiently transfected Expi293F cells in suspension culture using an Expifectamine transfection kit (Thermo Fisher Scientific, Cat no. A14524) as per the manufacturer&#x02019;s protocol. Post-transfection and expression, cell culture supernatants were harvested after 5&#x02013;6 days or until cells showed more than 60% cell death. The supernatant was passed through a Ni&#x02013;NTA column for protein purification. Bound proteins were eluted with 500 mM imidazole and were concentrated with an Amicon 10 kDa filter (Millipore, Burlington, MA, USA). Protein fractions were aliquoted and stored at &#x02212;80 &#x000b0;C.</p></sec><sec id="sec2dot7-vaccines-12-01396"><title>2.7. Labelling of RBD Protein with the Alexa Fluor-488</title><p>Purified RBD was tested using SDS PAGE to verify its purity and was used for the fluorophore labelling at a concentration of 1 mg/mL. Labelling of the RBD protein was performed using the Alexa Fluor Microscale Protein Labelling kit (Cat No. #A30006; Thermo Fisher Scientific) as per the manufacturer&#x02019;s instructions. Fluorophore-labelled RBDs were aliquoted and stored at &#x02212;20 &#x000b0;C for further use.</p></sec><sec id="sec2dot8-vaccines-12-01396"><title>2.8. Estimation of Antibody-Secreting Cells</title><p>Antigen-specific antibody-secreting cell estimation was performed as described by Crotty et al., 2004 [<xref rid="B16-vaccines-12-01396" ref-type="bibr">16</xref>] with slight modifications. PBMCs were washed after thawing with a complete RPMI medium, counted and cultured at a density of 3 million cells per sample, and added at 0.5 million cells per well in a 24-well plate. An additional 0.5 million cells were cultured in a medium without stimulants as a control. The polyclonal stimulation reagents used were protein A from <italic toggle="yes">Staphylococcus aureus</italic> (Sigma Aldrich, St. Louis, MO, USA, P7155), lectin from <italic toggle="yes">Phytolacca americana</italic> (pokeweed) (L9379), and ODN 2006 (TLR GRADE<sup>&#x000ae;</sup>) (synthetic) (Enzo Life Sciences, Farmingdale, NY, USA, -ALX-746-056-M001). The culture plate was kept in a CO<sub>2</sub> incubator for 5 days at 37 &#x000b0;C.</p><p>An ELISpot plate (Sigma Aldrich-MSIPS4510) was activated with 35% ethanol. After washing with PBST (PBS + 0.05% Tween 20) and PBS, the plate was coated with polyvalent goat anti-human Ig mix (Thermo Fisher Scientific&#x02014;H17000) and SARS-CoV-2 spike RBD at a concentration of 10 &#x003bc;g/mL in PBS. The plate was incubated overnight in the dark at 4 &#x000b0;C. Following coating, the plate was washed and blocked with 200 &#x000b5;L of a blocking buffer per well for at least 2 h at 37 &#x000b0;C or overnight at 4 &#x000b0;C. After culturing for 5 days, cells were washed and seeded onto the ELISpot plate (<xref rid="sec3dot3-vaccines-12-01396" ref-type="sec">Section 3.3</xref>). Subsequent steps included incubation with secondary antibodies [(goat anti-human IgA secondary antibody, Biotin (A18785), goat anti-human IgG Fc Bio Affinity (Thermo Fisher Scientific&#x02014;A18821), goat anti-human IgM secondary antibody, Biotin (Thermo Fisher Scientific&#x02014;PA1-86071)], Avidin-D-HRP (Thermo Fisher Scientific 18-4100-51), and a substrate solution. For every plate, the substrate was prepared by mixing 110 &#x000b5;L of an AEC-DMF solution (3-Amino-9-Ethylcarbazole in Dimethyl Formamide, 60 mg/mL) with 10 mL of 0.1 M sodium acetate and adding 165 &#x000b5;L of 3% H<sub>2</sub>O<sub>2</sub> (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) [Sigma Aldrich (323381)] after filtering the solution to remove any particulates. The plate was incubated for development of spots, rinsed gently with tap water, and dried overnight in the dark.</p><p>Spot counting was performed using the auto-counter feature of the CTL ImmunoSpot 7.0.36.0 device, which visualized and recorded the number of spots in each well. Quality control was performed to check for any errors in the counting, and corrections were made accordingly. The average of the spot-forming units (SFUs) from the unstimulated control wells was deducted from each of the stimulated sample SFU values.</p></sec><sec id="sec2dot9-vaccines-12-01396"><title>2.9. Estimation of Memory B Cells in the Peripheral Circulation</title><p>To estimate the percentage of RBD-specific memory B cells in the peripheral circulation of the study participants, a flow-cytometry-based method was utilized [<xref rid="B18-vaccines-12-01396" ref-type="bibr">18</xref>]. Flow cytometry was performed on a subset of samples only when sufficient PBMCs remained after culturing them for the ELISPOT assay. Alexa Fluor-488 (Invitrogen, Carlsbad, CA, USA, #A30006) fluorophore-labelled RBD was used as a probe for estimation of antigen-specific memory B cells. Briefly, 2 &#x000d7; 10<sup>6</sup> cells were first labelled with fixable viability dye (Invitrogen #L34964) and incubated for 15 min at 4 &#x000b0;C to distinguish between live and dead cells. The cells were washed twice by centrifugation with FACS buffer (1% FBS in PBS) and subsequently stained with antibodies targeting molecular markers that can differentiate memory B cells among PBMCs (<xref rid="vaccines-12-01396-t002" ref-type="table">Table 2</xref>). After incubation at 4 &#x000b0;C for 30 min and washing with FACS buffer, samples were acquired using a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA). The data were analyzed using FlowJo 10.3.0 (FlowJo LLC, Ashland, OR, USA). The gating strategy used was CD3<sup>&#x02212;</sup> (exclusion of T cells), CD19<sup>+</sup> and CD20<sup>+</sup> (pan-B cell markers), CD27<sup>+</sup>IgD<sup>&#x02212;</sup> (class-switched memory B cells), and RBD<sup>+</sup> (antigen-specific memory B cells).</p></sec><sec id="sec2dot10-vaccines-12-01396"><title>2.10. Statistics</title><p>All the data visualization and statistical analyses were performed using GraphPad Prism 10.2.0. Data were checked for normal distribution before analysis. The outliers were removed using the iterative Grubb&#x02019;s test (Alpha = 0.01). Datasets were visualized as bar charts depicting the median and interquartile range. Depending on the data, Mann&#x02013;Whitney U/Wilcoxon rank-sum, Kruskal&#x02013;Wallis, and Dunn&#x02019;s multiple comparison tests were used for statistical analyses, as appropriate. A <italic toggle="yes">p</italic> value of &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01396"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-vaccines-12-01396"><title>3.1. All Participants, Including Unvaccinated Individuals, Showed Marked Levels of Anti-RBD IgG Antibodies</title><p>The IgG antibody levels of the participants in our study were tested using RBD-specific IgG ELISA [<xref rid="B41-vaccines-12-01396" ref-type="bibr">41</xref>]. Vaccinated participants from all four vaccine groups showed a remarkable IgG response towards SARS-CoV-2 RBD, indicating that the vaccinations led to the development of a distinct humoral response against the virus (<xref rid="vaccines-12-01396-f001" ref-type="fig">Figure 1</xref>). However, the unvaccinated participants also showed an elevated RBD-specific IgG response, which suggests their possible exposure to SARS-CoV-2 during the pandemic. For this study, the blood samples from unvaccinated participants were collected during the Omicron surge in India, so it is likely that these participants contracted the virus during this period and remained asymptomatic [<xref rid="B44-vaccines-12-01396" ref-type="bibr">44</xref>]. The presence of post-recovery IgM antibodies for a prolonged time among these participants highlights the importance of these multimeric antibodies in tackling the virus. Similar observations have been made in other viral infections, where the higher avidity of these antibodies towards the antigens enables hosts to continue producing them in the backdrop of the persistent antigenic challenge [<xref rid="B4-vaccines-12-01396" ref-type="bibr">4</xref>,<xref rid="B45-vaccines-12-01396" ref-type="bibr">45</xref>].</p></sec><sec sec-type="subjects" id="sec3dot2-vaccines-12-01396"><title>3.2. Study Participants Exhibited RBD-Specific Memory B Cells in the Peripheral Circulation</title><p>Our analysis of the MBC responses to the SARS-CoV-2 RBD in the peripheral blood of the participants yielded mixed results. Flow cytometry analysis on PBMCs from 113 participants (85 vaccinated and 28 unvaccinated) revealed a higher percentage of RBD-specific memory B cells in the unvaccinated group as compared to any of the vaccinated groups. Although we recruited these unvaccinated participants based on their asymptomatic profile during the last three months, they showed a good antibody response against SARS-CoV-2 RBD. This is probably because of a fresh natural (asymptomatic) exposure of the unvaccinated participants to the pathogen at the time of the Omicron surge in the country [<xref rid="B44-vaccines-12-01396" ref-type="bibr">44</xref>] (<xref rid="vaccines-12-01396-f002" ref-type="fig">Figure 2</xref>). All the participants of vaccinated groups showed comparable percentages of RBD-specific memory B cells in the peripheral blood. Similar to our observation for the RBD-specific antibody levels in the plasma samples, the group of unvaccinated participants had a slightly higher number of RBD-specific memory B cells as compared to all the vaccinated groups in the peripheral circulation. However, there was no statistically significant difference seen among participants of vaccinated groups when compared with that of the unvaccinated participants.</p></sec><sec id="sec3dot3-vaccines-12-01396"><title>3.3. Magnitude of the RBD-Specific Antibody-Secreting B Cells Among Vaccinees from Different Vaccine Groups</title><p>To evaluate the magnitude of the RBD-specific antibody-secreting B cells among vaccinees from different vaccine groups, polyclonal stimulation of the PBMCs was performed, and the ability of the B cells to proliferate and secrete antigen-specific antibodies was tested [<xref rid="B16-vaccines-12-01396" ref-type="bibr">16</xref>]. The schematic diagram of the plate map and a representative image of the B cell ELISPOT plate are shown in <xref rid="vaccines-12-01396-f003" ref-type="fig">Figure 3</xref>A and <xref rid="vaccines-12-01396-f003" ref-type="fig">Figure 3</xref>B respectively. Our data revealed a distinct distribution of RBD-specific IgM, IgA, and IgG antibody-secreting B cells among the participants. The percentage of RBD-specific IgM antibody-secreting B cells was higher than that of IgA and IgG antibody-secreting B cells across all the analyzed groups (<xref rid="vaccines-12-01396-f004" ref-type="fig">Figure 4</xref>). However, it was almost similar across all the participant groups. The median percentage of IgA and IgG antibody-secreting B cells was slightly higher among participants vaccinated with the Corbevax and Sputnik Light as compared with the other groups, including the unvaccinated participants. Covaxin also mounted a slightly better IgA response compared to the unvaccinated group. There were no statistically significant differences in the ASC response between the groups because of considerable variability, as evident from <xref rid="vaccines-12-01396-f004" ref-type="fig">Figure 4</xref>. The increase in the median percentage of IgA and IgG antibody-secreting B cells in the participants of the Corbevax and Sputnik Light groups, as well as the IgA response in the Covaxin-vaccinated participants, is of significance when considering the vaccine-induced immune memory response. Even though these groups had a lower level of RBD-specific IgG antibodies in their plasma samples (<xref rid="vaccines-12-01396-f001" ref-type="fig">Figure 1</xref>) and fewer RBD-specific memory B cells in circulation compared to the unvaccinated group (<xref rid="vaccines-12-01396-f002" ref-type="fig">Figure 2</xref>), a reversal in the pattern was observed in their ASC responses. It should be noted that a single-dose Sputnik Light vaccine, resulted in a marked level of the RBD-specific IgG antibody-secreting B cells comparable to those produced by other vaccines after two doses.</p></sec><sec id="sec3dot4-vaccines-12-01396"><title>3.4. Temporal Patterns in the RBD-Specific Antibody-Secreting B Cells Post-Vaccination</title><p>To test the durability of the ASC response of the participants of different vaccine groups, we categorized the samples of each vaccination group by 4&#x02013;6 months and beyond 6 months post-vaccination. The levels of IgA- and IgM-secreting B cells among the Corbevax-immunized participants post-6-months of vaccination did not differ significantly from the participants in the unvaccinated group (<xref rid="vaccines-12-01396-f005" ref-type="fig">Figure 5</xref>A). However, they exhibited a statistically significant increase in RBD-specific IgG ASC suggesting an enhanced IgG antibody response among these participants over time (<xref rid="vaccines-12-01396-f005" ref-type="fig">Figure 5</xref>A). However, at early time points, a slight enhancement in the median of the ASC response for only IgG was observed among the Corbevax-vaccinated participants (<xref rid="app1-vaccines-12-01396" ref-type="app">Supplementary Figure S1</xref>). The ASC response after Covaxin administration remained similar to that of the unvaccinated group among the samples obtained post-6-months of vaccination (<xref rid="vaccines-12-01396-f005" ref-type="fig">Figure 5</xref>B). We observed an increase in the median RBD-specific IgA and IgG SFUs at an early time point with a significant inter-individual variation (<xref rid="app1-vaccines-12-01396" ref-type="app">Supplementary Figure S2</xref>). However, the above result cannot be considered conclusive, as the number of samples in the 4&#x02013;6 months post-vaccination group is not sufficient. Participants immunized with Covishield did not show a noticeable trend in the memory B cell immune response. The percentage of RBD-specific antibody-secreting B cells remained similar for 4&#x02013;6 months and thereafter in these participants (<xref rid="vaccines-12-01396-f005" ref-type="fig">Figure 5</xref>C and <xref rid="app1-vaccines-12-01396" ref-type="app">Supplementary Figure S3</xref>). Individuals who received the Sputnik Light vaccine displayed an enhancement in the levels of RBD-specific IgA and IgG antibody-secreting B cells after 6 months post-vaccination (<xref rid="vaccines-12-01396-f005" ref-type="fig">Figure 5</xref>D). However, we did not observe a marked difference in this regard at early time points (<xref rid="app1-vaccines-12-01396" ref-type="app">Supplementary Figure S4</xref>).</p><p>This observation suggests the development of a durable and broader antibody response over time following Corbevax and Sputnik Light vaccination. A limitation in drawing definitive conclusions about the impact of various vaccines on the temporal dynamics of ASC responses is the relatively small number of samples collected after vaccination with Covaxin, Covishield, and Sputnik Light within the 4- to 6-month time window (<xref rid="app1-vaccines-12-01396" ref-type="app">Supplementary Figures S1&#x02013;S4</xref>).</p></sec><sec id="sec3dot5-vaccines-12-01396"><title>3.5. No Sex-Specific Disparities Observed in Serological or Memory Immune Responses</title><p>A considerable number of males and females participated in this study, as evident from <xref rid="vaccines-12-01396-t001" ref-type="table">Table 1</xref>B. We performed a sex-disaggregated analysis of the immune responses to evaluate any disparities between males and females. As shown in <xref rid="vaccines-12-01396-f006" ref-type="fig">Figure 6</xref>, our analysis revealed no statistically significant differences in serological immune responses or B cell memory responses between male and female participants. This finding indicates that sex does not appear to influence the B cell immune response to vaccination. Despite the lower number of vaccinated females compared to males, our data suggest that the immune responses are comparable across sexes.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01396"><title>4. Discussion</title><p>Understanding the immune memory response is crucial for gaining insights into the longevity of the protection against pathogens. The memory responses of T and B cells and their functionality are shaped not only by the antigens of a pathogen and their presentations but also by the interactions between these cell types [<xref rid="B46-vaccines-12-01396" ref-type="bibr">46</xref>]. The B cell memory phenotype is generated as a result of multiple iterations of antigen-based selection of antibody-secreting B cell populations [<xref rid="B47-vaccines-12-01396" ref-type="bibr">47</xref>]. The instability of the viral genome and the resulting mutations in the antigens, particularly the spike protein in the case of SARS-CoV-2, diminishes the impact of B cell memory response during a reinfection or a breakthrough infection [<xref rid="B48-vaccines-12-01396" ref-type="bibr">48</xref>]. It has been shown that MBC responses were more pronounced when individuals experienced a natural infection followed by a single vaccine dose as opposed to vaccination alone [<xref rid="B49-vaccines-12-01396" ref-type="bibr">49</xref>]. In our study, it was observed that even the unvaccinated individuals exhibited antibody response as well as memory B cells with proliferative capability in their peripheral circulation, likely due to asymptomatic infections during the Omicron wave [<xref rid="B44-vaccines-12-01396" ref-type="bibr">44</xref>]. This highlights the complex interplay between vaccination, prior infection, virus-specific MBC generation, and maintenance.</p><p>The generation and durability of MBCs has been linked to the severity of the disease, where moderate to severe infections have resulted in generating the ability to mount a better B cell recall response. Several studies show that the overall antibody titres decline rapidly a few months following infection and vaccination after attaining a peak in the initial days [<xref rid="B50-vaccines-12-01396" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-12-01396" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-12-01396" ref-type="bibr">52</xref>]. Relatively few studies have been performed to gain insight into the protection provided by memory B cells. Most of the studies in this field have focused on the mRNA-based vaccines [<xref rid="B53-vaccines-12-01396" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-12-01396" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-12-01396" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-12-01396" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01396" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-12-01396" ref-type="bibr">58</xref>]. Various aspects of immunological memory produced by BNT162b2 (Pfizer-BioNTech) vaccination against SARS-CoV-2 have been widely studied [<xref rid="B57-vaccines-12-01396" ref-type="bibr">57</xref>,<xref rid="B59-vaccines-12-01396" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-12-01396" ref-type="bibr">60</xref>]. In India, where the BNT162b2 vaccine was rarely administered, such studies are lacking.</p><p>Among the vaccinated groups, we found variations in the fraction of ASCs induced by different vaccines. Notably, BECOV2D and Gam-COVID-Vac showed promising results, with a slight increase in the number of ASCs six months after vaccination, similar to what was previously observed in BNT162b2 [<xref rid="B59-vaccines-12-01396" ref-type="bibr">59</xref>,<xref rid="B61-vaccines-12-01396" ref-type="bibr">61</xref>]. On the other hand, though BBV152 and AZD1222 induced a considerable number of ASCs after vaccination, they did not show any significant change in the B cell recall response over time. These vaccines induced a B cell recall response like a mild infection, but the temporal dynamics depended on the specific vaccine. Although some of the vaccinated individuals got infected during the subsequent waves of COVID-19, it is well established that vaccination reduced the severity of the disease and hospitalizations. This is possibly because of the broader cellular memory responses generated by these vaccines which tackled the virus in an efficient manner and hence reduced the disease severity [<xref rid="B3-vaccines-12-01396" ref-type="bibr">3</xref>].</p><p>Our study has some limitations that should be addressed in future research. First, a larger sample size would provide a clear understanding of the temporal dynamics of the ASC response mounted by different vaccines. It would have been ideal to have access to pre-pandemic PBMCs and plasma samples. The lack of such samples limits our ability to distinguish between infection-induced and infection as well as vaccination-induced responses. Additionally, our study solely focused on B cell responses. Although studies have analyzed T cell memory response by different vaccines, analysis of both T and B cell memory responses on the same group of participants would add a holistic understanding of the immune memory response mounted by vaccination. Further, we observed a substantial interindividual variation among these responses at the level of RBD-specific memory B cells in the peripheral circulation as well as in the secretion of antigen-specific antibodies, reflecting immunological heterogeneity among humans [<xref rid="B62-vaccines-12-01396" ref-type="bibr">62</xref>]. While the MBC phenotyping method we followed (CD3<sup>&#x02212;</sup>, CD19<sup>+</sup>, CD20<sup>+</sup>, CD27<sup>+</sup>, IgD<sup>&#x02212;</sup>) is widely accepted, recent research suggests that CD27 may not be able to serve as an ideal marker for circulating MBCs [<xref rid="B63-vaccines-12-01396" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-12-01396" ref-type="bibr">64</xref>]. Despite these limitations, this study improves our understanding of the memory B cell response induced by various COVID-19 vaccines used in India, an aspect which was previously underexplored [<xref rid="B65-vaccines-12-01396" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-12-01396" ref-type="bibr">66</xref>].</p></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01396"><title>5. Conclusions</title><p>The levels of memory B cells generated by vaccination or natural infection serve as a better immune correlate of protection than antibody levels in the blood circulation [<xref rid="B67-vaccines-12-01396" ref-type="bibr">67</xref>]. Our study highlights the immune memory response, particularly the B cell memory response, generated after vaccination against COVID-19. Although we did not find any significant difference between the MBC responses of vaccinated and unvaccinated (presumably infected) participants, it should be noted that vaccinated individuals demonstrated an enhanced ability to secrete RBD-specific antibodies during re-exposure. This suggests that while vaccination may not significantly alter MBC numbers in a highly exposed population, it does improve the breadth and magnitude of the B cell recall response. A high percentage of individuals infected during the Omicron wave in India remained asymptomatic [<xref rid="B44-vaccines-12-01396" ref-type="bibr">44</xref>]. This is potentially the reason for the unvaccinated individuals exhibiting high levels of RBD-specific IgG antibodies, as observed in this study. They also showed the presence of RBD-specific B cells in their peripheral circulation. However, the vaccinated participants, especially those vaccinated with Corbevax and Sputnik Light, showed better response in terms of secreting RBD-specific antibodies after polyclonal stimulation. This suggests an effective and durable B cell memory response generated by these vaccines. These findings contribute to our understanding of vaccine-induced immune memory and may inform future vaccination strategies, including the potential need for booster doses. This knowledge could also help government bodies in making policy decisions, including the preferential use of a particular vaccine development platform. This study is also unique in guiding tailored and more equitable vaccination strategies based on the understanding of the durability of the memory response of B cells and their ability to proliferate and secrete antigen-specific antibodies. Further research is needed to fully evaluate the long-term protection conferred by these vaccines, especially in the context of emerging SARS-CoV-2 variants. Our study underscores the importance of continued research into vaccine-induced immune responses to guide public health strategies in the management of COVID-19 or similar infectious diseases in the future.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to acknowledge Sankalp and Rohit Dhaka from ESIC Medical College and Hospital, Faridabad, for their help with participant enrolment. We also thank Amit Kumar Yadav, Aftab Hussain, Richa Kumari, Molly Singh, Deepak Rathore, Akshay Binayake, Aymaan Jaheer, Manas Ranjan Tripathy, and Jitender Chandilla, Immunobiology and Immunotherapy laboratory, BRIC-THSTI, Faridabad, for the suggestions and help. We are thankful to the participants for donating their blood samples, which made this study feasible. We are also thankful to the BEI resources for providing the RBD-Wuhan plasmid NR-52309. The graphical abstract was created using Microsoft PowerPoint 2016 and Excalidraw (<uri xlink:href="https://excalidraw.com/">https://excalidraw.com/</uri>, accessed on 11 September 2024) with graphs from GraphPad Prism 10.3 and icons from NIH Bioart Source (<uri xlink:href="https://bioart.niaid.nih.gov">https://bioart.niaid.nih.gov</uri>, accessed on 9 December 2024).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-12-01396"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines12121396/s1">https://www.mdpi.com/article/10.3390/vaccines12121396/s1</uri>, Figures S1&#x02013;S4: Fraction of the RBD specific ASC (IgA, IgG and IgM) to depict temporal changes at 4&#x02013;6 months. Figure S1: among Corbevax vaccinated versus unvaccinated individuals. Figure S2: among Covaxin vaccinated versus unvaccinated individuals. Figure S3: among Covishield vaccinated versus unvaccinated individuals. Figure S4: among Sputnik Light vaccinated versus unvaccinated individuals.</p><supplementary-material id="vaccines-12-01396-s001" position="float" content-type="local-data"><media xlink:href="vaccines-12-01396-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>A.A. (Atharv Athavale)&#x02014;performed the experiments; made tables and figures; and wrote, reviewed, and edited the different versions of the manuscript; A.G. and N.A.&#x02014;collected samples and performed the experiments; A.S., J.D. and S.R.&#x02014;performed the experiments; S.K.U.&#x02014;conceptualized, edited, and reviewed the different versions of the manuscript; S.S.&#x02014;provided the RBD reagent and reviewed the manuscript; A.K.P.&#x02014;provided samples for the study and reviewed the different versions of the manuscript; R.C.R.&#x02014;conceptualized the study; wrote the manuscript; and reviewed and edited the different versions of the manuscript, tables, and figures; A.A. (Amit Awasthi)&#x02014;conceptualized the study and reviewed the different versions of the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committees of Translational Health Science and Technology Institute, Faridabad [Ref No: THS 1.8.1/(130), 27 October 2021] and ESIC Medical College and Hospital, Faridabad [File no. 134 X/11/13/2021-IEC/43, 27 October 2021].</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The authors will provide data while keeping the participants&#x02019; details confidential and as per the journal policy.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no known competing financial interests that could have influenced this work.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01396"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pollard</surname><given-names>A.J.</given-names></name>
<name><surname>Bijker</surname><given-names>E.M.</given-names></name>
</person-group><article-title>A Guide to Vaccinology: From Basic Principles to New Developments</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>83</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id><pub-id pub-id-type="pmid">33353987</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01396"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Subbarao</surname><given-names>K.</given-names></name>
</person-group><article-title>The Success of SARS-CoV-2 Vaccines and Challenges Ahead</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><fpage>1111</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.06.016</pub-id><pub-id pub-id-type="pmid">34265245</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01396"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciabattini</surname><given-names>A.</given-names></name>
<name><surname>Pastore</surname><given-names>G.</given-names></name>
<name><surname>Lucchesi</surname><given-names>S.</given-names></name>
<name><surname>Montesi</surname><given-names>G.</given-names></name>
<name><surname>Costagli</surname><given-names>S.</given-names></name>
<name><surname>Polvere</surname><given-names>J.</given-names></name>
<name><surname>Fiorino</surname><given-names>F.</given-names></name>
<name><surname>Pettini</surname><given-names>E.</given-names></name>
<name><surname>Lippi</surname><given-names>A.</given-names></name>
<name><surname>Ancillotti</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>1706</elocation-id><pub-id pub-id-type="doi">10.3390/cells12131706</pub-id><pub-id pub-id-type="pmid">37443740</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01396"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chua</surname><given-names>C.-L.</given-names></name>
<name><surname>Sam</surname><given-names>I.-C.</given-names></name>
<name><surname>Chiam</surname><given-names>C.-W.</given-names></name>
<name><surname>Chan</surname><given-names>Y.-F.</given-names></name>
</person-group><article-title>The Neutralizing Role of IgM during Early Chikungunya Virus Infection</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0171989</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0171989</pub-id><pub-id pub-id-type="pmid">28182795</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01396"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lizeng</surname><given-names>Q.</given-names></name>
<name><surname>Nilsson</surname><given-names>C.</given-names></name>
<name><surname>Sourial</surname><given-names>S.</given-names></name>
<name><surname>Andersson</surname><given-names>S.</given-names></name>
<name><surname>Larsen</surname><given-names>O.</given-names></name>
<name><surname>Aaby</surname><given-names>P.</given-names></name>
<name><surname>Ehnlund</surname><given-names>M.</given-names></name>
<name><surname>Bj&#x000f6;rling</surname><given-names>E.</given-names></name>
</person-group><article-title>Potent Neutralizing Serum Immunoglobulin A (IgA) in Human Immunodeficiency Virus Type 2-Exposed IgG-Seronegative Individuals</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>7016</fpage><lpage>7022</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.13.7016-7022.2004</pub-id><pub-id pub-id-type="pmid">15194778</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01396"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pu&#x00161;nik</surname><given-names>J.</given-names></name>
<name><surname>K&#x000f6;nig</surname><given-names>J.</given-names></name>
<name><surname>Mai</surname><given-names>K.</given-names></name>
<name><surname>Richter</surname><given-names>E.</given-names></name>
<name><surname>Zorn</surname><given-names>J.</given-names></name>
<name><surname>Proksch</surname><given-names>H.</given-names></name>
<name><surname>Schulte</surname><given-names>B.</given-names></name>
<name><surname>Alter</surname><given-names>G.</given-names></name>
<name><surname>Streeck</surname><given-names>H.</given-names></name>
</person-group><article-title>Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0076022</fpage><pub-id pub-id-type="doi">10.1128/jvi.00760-22</pub-id><pub-id pub-id-type="pmid">35862718</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01396"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quast</surname><given-names>I.</given-names></name>
<name><surname>Tarlinton</surname><given-names>D.</given-names></name>
</person-group><article-title>B Cell Memory: Understanding COVID-19</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.01.014</pub-id><pub-id pub-id-type="pmid">33513337</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01396"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurosaki</surname><given-names>T.</given-names></name>
<name><surname>Kometani</surname><given-names>K.</given-names></name>
<name><surname>Ise</surname><given-names>W.</given-names></name>
</person-group><article-title>Memory B Cells</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1038/nri3802</pub-id><pub-id pub-id-type="pmid">25677494</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01396"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>T.</given-names></name>
<name><surname>Moran</surname><given-names>I.</given-names></name>
<name><surname>Shinnakasu</surname><given-names>R.</given-names></name>
<name><surname>Phan</surname><given-names>T.G.</given-names></name>
<name><surname>Kurosaki</surname><given-names>T.</given-names></name>
</person-group><article-title>Generation of Memory B Cells and Their Reactivation</article-title><source>Immunol. Rev.</source><year>2018</year><volume>283</volume><fpage>138</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1111/imr.12640</pub-id><pub-id pub-id-type="pmid">29664566</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01396"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raskov</surname><given-names>H.</given-names></name>
<name><surname>Orhan</surname><given-names>A.</given-names></name>
<name><surname>Christensen</surname><given-names>J.P.</given-names></name>
<name><surname>G&#x000f6;genur</surname><given-names>I.</given-names></name>
</person-group><article-title>Cytotoxic CD8<sup>+</sup> T Cells in Cancer and Cancer Immunotherapy</article-title><source>Br. J. Cancer</source><year>2021</year><volume>124</volume><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-01048-4</pub-id><pub-id pub-id-type="pmid">32929195</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01396"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laidlaw</surname><given-names>B.J.</given-names></name>
<name><surname>Craft</surname><given-names>J.E.</given-names></name>
<name><surname>Kaech</surname><given-names>S.M.</given-names></name>
</person-group><article-title>The Multifaceted Role of CD4<sup>+</sup> T Cells in CD8<sup>+</sup> T Cell Memory</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/nri.2015.10</pub-id><pub-id pub-id-type="pmid">26781939</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01396"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palm</surname><given-names>A.-K.E.</given-names></name>
<name><surname>Henry</surname><given-names>C.</given-names></name>
</person-group><article-title>Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>1787</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01787</pub-id><pub-id pub-id-type="pmid">31417562</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01396"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tarlinton</surname><given-names>D.</given-names></name>
<name><surname>Good-Jacobson</surname><given-names>K.</given-names></name>
</person-group><article-title>Diversity among Memory B Cells: Origin, Consequences, and Utility</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1126/science.1241146</pub-id><pub-id pub-id-type="pmid">24031013</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01396"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mesin</surname><given-names>L.</given-names></name>
<name><surname>Ersching</surname><given-names>J.</given-names></name>
<name><surname>Victora</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Germinal Center B Cell Dynamics</article-title><source>Immunity</source><year>2016</year><volume>45</volume><fpage>471</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.09.001</pub-id><pub-id pub-id-type="pmid">27653600</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01396"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruhn</surname><given-names>M.</given-names></name>
<name><surname>Obara</surname><given-names>M.</given-names></name>
<name><surname>Chiyyeadu</surname><given-names>A.</given-names></name>
<name><surname>Costa</surname><given-names>B.</given-names></name>
<name><surname>Salam</surname><given-names>A.</given-names></name>
<name><surname>Ziegler</surname><given-names>A.</given-names></name>
<name><surname>Waltl</surname><given-names>I.</given-names></name>
<name><surname>Pavlou</surname><given-names>A.</given-names></name>
<name><surname>Bonifacius</surname><given-names>A.</given-names></name>
<name><surname>Hoffmann</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Memory B Cells Anticipate SARS-CoV-2 Variants through Somatic Hypermutation</article-title><source>J. Infect.</source><year>2024</year><volume>88</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2023.10.020</pub-id><pub-id pub-id-type="pmid">37913848</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01396"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crotty</surname><given-names>S.</given-names></name>
<name><surname>Aubert</surname><given-names>R.D.</given-names></name>
<name><surname>Glidewell</surname><given-names>J.</given-names></name>
<name><surname>Ahmed</surname><given-names>R.</given-names></name>
</person-group><article-title>Tracking Human Antigen-Specific Memory B Cells: A Sensitive and Generalized ELISPOT System</article-title><source>J. Immunol. Methods</source><year>2004</year><volume>286</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2003.12.015</pub-id><pub-id pub-id-type="pmid">15087226</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01396"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartley</surname><given-names>G.E.</given-names></name>
<name><surname>Edwards</surname><given-names>E.S.J.</given-names></name>
<name><surname>O&#x02019;Hehir</surname><given-names>R.E.</given-names></name>
<name><surname>Van Zelm</surname><given-names>M.C.</given-names></name>
</person-group><article-title>New Insights into Human Immune Memory from <sc>SARS-C</sc>o<sc>V</sc>-2 Infection and Vaccination</article-title><source>Allergy</source><year>2022</year><volume>77</volume><fpage>3553</fpage><lpage>3566</lpage><pub-id pub-id-type="doi">10.1111/all.15502</pub-id><pub-id pub-id-type="pmid">36048132</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01396"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nayak</surname><given-names>K.</given-names></name>
<name><surname>Gottimukkala</surname><given-names>K.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Reddy</surname><given-names>E.S.</given-names></name>
<name><surname>Edara</surname><given-names>V.V.</given-names></name>
<name><surname>Kauffman</surname><given-names>R.</given-names></name>
<name><surname>Floyd</surname><given-names>K.</given-names></name>
<name><surname>Mantus</surname><given-names>G.</given-names></name>
<name><surname>Savargaonkar</surname><given-names>D.</given-names></name>
<name><surname>Goel</surname><given-names>P.K.</given-names></name>
<etal/>
</person-group><article-title>Characterization of Neutralizing versus Binding Antibodies and Memory B Cells in COVID-19 Recovered Individuals from India</article-title><source>Virology</source><year>2021</year><volume>558</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2021.02.002</pub-id><pub-id pub-id-type="pmid">33706207</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01396"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Subramaniam</surname><given-names>A.</given-names></name>
</person-group><article-title>Targeting Spike Protein: Modified Antibody for Broad-Spectrum Binding to Coronaviruses: An In Silico Study</article-title><source>Virol. Immunol. J.</source><year>2023</year><volume>7</volume><fpage>000324</fpage><pub-id pub-id-type="doi">10.23880/vij-16000324</pub-id></element-citation></ref><ref id="B20-vaccines-12-01396"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ejemel</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Hou</surname><given-names>S.</given-names></name>
<name><surname>Schiller</surname><given-names>Z.A.</given-names></name>
<name><surname>Tree</surname><given-names>J.A.</given-names></name>
<name><surname>Wallace</surname><given-names>A.</given-names></name>
<name><surname>Amcheslavsky</surname><given-names>A.</given-names></name>
<name><surname>Kurt Yilmaz</surname><given-names>N.</given-names></name>
<name><surname>Buttigieg</surname><given-names>K.R.</given-names></name>
<name><surname>Elmore</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>A Cross-Reactive Human IgA Monoclonal Antibody Blocks SARS-CoV-2 Spike-ACE2 Interaction</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>4198</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18058-8</pub-id><pub-id pub-id-type="pmid">32826914</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01396"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hajilooi</surname><given-names>M.</given-names></name>
<name><surname>Keramat</surname><given-names>F.</given-names></name>
<name><surname>Moazenian</surname><given-names>A.</given-names></name>
<name><surname>Rastegari-Pouyani</surname><given-names>M.</given-names></name>
<name><surname>Solgi</surname><given-names>G.</given-names></name>
</person-group><article-title>The Quantity and Quality of Anti-SARS-CoV-2 Antibodies Show Contrariwise Association with COVID-19 Severity: Lessons Learned from IgG Avidity</article-title><source>Med. Microbiol. Immunol.</source><year>2023</year><volume>212</volume><fpage>203</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s00430-023-00763-y</pub-id><pub-id pub-id-type="pmid">37103583</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01396"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vadrevu</surname><given-names>K.M.</given-names></name>
<name><surname>Ganneru</surname><given-names>B.</given-names></name>
<name><surname>Reddy</surname><given-names>S.</given-names></name>
<name><surname>Jogdand</surname><given-names>H.</given-names></name>
<name><surname>Raju</surname><given-names>D.</given-names></name>
<name><surname>Sapkal</surname><given-names>G.</given-names></name>
<name><surname>Yadav</surname><given-names>P.</given-names></name>
<name><surname>Reddy</surname><given-names>P.</given-names></name>
<name><surname>Verma</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Persistence of Immunity and Impact of Third Dose of Inactivated COVID-19 Vaccine against Emerging Variants</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>12038</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-16097-3</pub-id><pub-id pub-id-type="pmid">35835822</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01396"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>N.</given-names></name>
<name><surname>Athavale</surname><given-names>A.</given-names></name>
<name><surname>Tripathi</surname><given-names>A.H.</given-names></name>
<name><surname>Subramaniam</surname><given-names>A.</given-names></name>
<name><surname>Upadhyay</surname><given-names>S.K.</given-names></name>
<name><surname>Pandey</surname><given-names>A.K.</given-names></name>
<name><surname>Rai</surname><given-names>R.C.</given-names></name>
<name><surname>Awasthi</surname><given-names>A.</given-names></name>
</person-group><article-title>To Be Remembered: B Cell Memory Response against SARS-CoV-2 and Its Variants in Vaccinated and Unvaccinated Individuals</article-title><source>Scand. J. Immunol.</source><year>2024</year><volume>99</volume><fpage>e13345</fpage><pub-id pub-id-type="doi">10.1111/sji.13345</pub-id><pub-id pub-id-type="pmid">38441373</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01396"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thuluva</surname><given-names>S.</given-names></name>
<name><surname>Paradkar</surname><given-names>V.</given-names></name>
<name><surname>Gunneri</surname><given-names>S.</given-names></name>
<name><surname>Yerroju</surname><given-names>V.</given-names></name>
<name><surname>Mogulla</surname><given-names>R.</given-names></name>
<name><surname>Suneetha</surname><given-names>P.V.</given-names></name>
<name><surname>Turaga</surname><given-names>K.</given-names></name>
<name><surname>Kyasani</surname><given-names>M.</given-names></name>
<name><surname>Manoharan</surname><given-names>S.K.</given-names></name>
<name><surname>Adabala</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity and Safety of Biological E&#x02019;s CORBEVAX<sup>TM</sup> Vaccine Compared to COVISHIELD<sup>TM</sup> (ChAdOx1 nCoV-19) Vaccine Studied in a Phase-3, Single Blind, Multicentre, Randomized Clinical Trial</article-title><source>Hum. Vaccin. Immunother.</source><year>2023</year><volume>19</volume><fpage>2203632</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2203632</pub-id><pub-id pub-id-type="pmid">37113012</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01396"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tukhvatulin</surname><given-names>A.I.</given-names></name>
<name><surname>Dolzhikova</surname><given-names>I.V.</given-names></name>
<name><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name>
<name><surname>Zubkova</surname><given-names>O.V.</given-names></name>
<name><surname>Dzharullaeva</surname><given-names>A.S.</given-names></name>
<name><surname>Kovyrshina</surname><given-names>A.V.</given-names></name>
<name><surname>Lubenets</surname><given-names>N.L.</given-names></name>
<name><surname>Grousova</surname><given-names>D.M.</given-names></name>
<name><surname>Erokhova</surname><given-names>A.S.</given-names></name>
<name><surname>Botikov</surname><given-names>A.G.</given-names></name>
<etal/>
</person-group><article-title>An Open, Non-Randomised, Phase 1/2 Trial on the Safety, Tolerability, and Immunogenicity of Single-Dose Vaccine &#x0201c;Sputnik Light&#x0201d; for Prevention of Coronavirus Infection in Healthy Adults</article-title><source>Lancet Reg. Health Eur.</source><year>2021</year><volume>11</volume><fpage>100241</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100241</pub-id><pub-id pub-id-type="pmid">34746910</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01396"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Russian Direct Investment Fund</collab>
</person-group><source>Sputnik Light: A Single-Component Stand-Alone Vaccine Against COVID-19 and a Perfect Booster</source><publisher-name>Russian Direct Investment Fund</publisher-name><publisher-loc>Moscow, Russia</publisher-loc><year>2021</year></element-citation></ref><ref id="B27-vaccines-12-01396"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ella</surname><given-names>R.</given-names></name>
<name><surname>Vadrevu</surname><given-names>K.M.</given-names></name>
<name><surname>Jogdand</surname><given-names>H.</given-names></name>
<name><surname>Prasad</surname><given-names>S.</given-names></name>
<name><surname>Reddy</surname><given-names>S.</given-names></name>
<name><surname>Sarangi</surname><given-names>V.</given-names></name>
<name><surname>Ganneru</surname><given-names>B.</given-names></name>
<name><surname>Sapkal</surname><given-names>G.</given-names></name>
<name><surname>Yadav</surname><given-names>P.</given-names></name>
<name><surname>Abraham</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBV152: A Double-Blind, Randomised, Phase 1 Trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30942-7</pub-id><pub-id pub-id-type="pmid">33485468</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01396"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Voysey</surname><given-names>M.</given-names></name>
<name><surname>Clemens</surname><given-names>S.A.C.</given-names></name>
<name><surname>Madhi</surname><given-names>S.A.</given-names></name>
<name><surname>Weckx</surname><given-names>L.Y.</given-names></name>
<name><surname>Folegatti</surname><given-names>P.M.</given-names></name>
<name><surname>Aley</surname><given-names>P.K.</given-names></name>
<name><surname>Angus</surname><given-names>B.</given-names></name>
<name><surname>Baillie</surname><given-names>V.L.</given-names></name>
<name><surname>Barnabas</surname><given-names>S.L.</given-names></name>
<name><surname>Bhorat</surname><given-names>Q.E.</given-names></name>
<etal/>
</person-group><article-title>Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmid">33306989</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01396"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Logunov</surname><given-names>D.Y.</given-names></name>
<name><surname>Dolzhikova</surname><given-names>I.V.</given-names></name>
<name><surname>Zubkova</surname><given-names>O.V.</given-names></name>
<name><surname>Tukhvatulin</surname><given-names>A.I.</given-names></name>
<name><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name>
<name><surname>Dzharullaeva</surname><given-names>A.S.</given-names></name>
<name><surname>Grousova</surname><given-names>D.M.</given-names></name>
<name><surname>Erokhova</surname><given-names>A.S.</given-names></name>
<name><surname>Kovyrshina</surname><given-names>A.V.</given-names></name>
<name><surname>Botikov</surname><given-names>A.G.</given-names></name>
<etal/>
</person-group><article-title>Safety and Immunogenicity of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1/2 Studies from Russia</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmid">32896291</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01396"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Biological</surname><given-names>E.</given-names></name>
</person-group><source>Limited. CORBEVAX Is India&#x02019;s 1st Indigenously Developed Protein Sub-Unit COVID-19 Vaccine</source><publisher-name>Biological E. Limited</publisher-name><publisher-loc>Hyderabad, India</publisher-loc><year>2021</year></element-citation></ref><ref id="B31-vaccines-12-01396"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishna</surname><given-names>B.</given-names></name>
<name><surname>Gupta</surname><given-names>A.</given-names></name>
<name><surname>Meena</surname><given-names>K.</given-names></name>
<name><surname>Gaba</surname><given-names>A.</given-names></name>
<name><surname>Krishna</surname><given-names>S.</given-names></name>
<name><surname>Jyoti</surname><given-names>R.</given-names></name>
<name><surname>Aeron</surname><given-names>N.</given-names></name>
<name><surname>Prashanth</surname><given-names>S.</given-names></name>
<name><surname>Samriti</surname></name>
<name><surname>Ganapathy</surname><given-names>U.</given-names></name>
</person-group><article-title>Prevalence, Severity, and Risk Factor of Breakthrough Infection after Vaccination with Either the Covaxin or the Covishield among Healthcare Workers: A Nationwide Cross-Sectional Study</article-title><source>J. Anaesthesiol. Clin. Pharmacol.</source><year>2022</year><volume>38</volume><fpage>S66</fpage><lpage>S78</lpage><pub-id pub-id-type="doi">10.4103/joacp.joacp_436_21</pub-id><pub-id pub-id-type="pmid">36060166</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01396"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malhotra</surname><given-names>A.</given-names></name>
</person-group><article-title>Curing the Pandemic of Misinformation on COVID-19 mRNA Vaccines through Real Evidence-Based Medicine&#x02014;Part 2</article-title><source>J. Insul. Resist.</source><year>2022</year><volume>5</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.4102/jir.v5i1.72</pub-id></element-citation></ref><ref id="B33-vaccines-12-01396"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vallejo</surname><given-names>A.</given-names></name>
<name><surname>Vizcarra</surname><given-names>P.</given-names></name>
<name><surname>Mart&#x000ed;n-Hondarza</surname><given-names>A.</given-names></name>
<name><surname>G&#x000f3;mez-Maldonado</surname><given-names>S.</given-names></name>
<name><surname>Haemmerle</surname><given-names>J.</given-names></name>
<name><surname>Velasco</surname><given-names>H.</given-names></name>
<name><surname>Casado</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Impact of SARS-CoV-2-Specific Memory B Cells on the Immune Response after mRNA-Based Comirnaty Vaccine in Seronegative Health Care Workers</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>1002748</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.1002748</pub-id><pub-id pub-id-type="pmid">36212856</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01396"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cox</surname><given-names>R.J.</given-names></name>
<name><surname>Brokstad</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Not Just Antibodies: B Cells and T Cells Mediate Immunity to COVID-19</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>581</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00436-4</pub-id><pub-id pub-id-type="pmid">32839569</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01396"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kudriavtsev</surname><given-names>A.V.</given-names></name>
<name><surname>Vakhrusheva</surname><given-names>A.V.</given-names></name>
<name><surname>Novoseletsky</surname><given-names>V.N.</given-names></name>
<name><surname>Bozdaganyan</surname><given-names>M.E.</given-names></name>
<name><surname>Shaitan</surname><given-names>K.V.</given-names></name>
<name><surname>Kirpichnikov</surname><given-names>M.P.</given-names></name>
<name><surname>Sokolova</surname><given-names>O.S.</given-names></name>
</person-group><article-title>Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>1603</elocation-id><pub-id pub-id-type="doi">10.3390/v14081603</pub-id><pub-id pub-id-type="pmid">35893668</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01396"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>C.O.</given-names></name>
<name><surname>Jette</surname><given-names>C.A.</given-names></name>
<name><surname>Abernathy</surname><given-names>M.E.</given-names></name>
<name><surname>Dam</surname><given-names>K.-M.A.</given-names></name>
<name><surname>Esswein</surname><given-names>S.R.</given-names></name>
<name><surname>Gristick</surname><given-names>H.B.</given-names></name>
<name><surname>Malyutin</surname><given-names>A.G.</given-names></name>
<name><surname>Sharaf</surname><given-names>N.G.</given-names></name>
<name><surname>Huey-Tubman</surname><given-names>K.E.</given-names></name>
<name><surname>Lee</surname><given-names>Y.E.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 Neutralizing Antibody Structures Inform Therapeutic Strategies</article-title><source>Nature</source><year>2020</year><volume>588</volume><fpage>682</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2852-1</pub-id><pub-id pub-id-type="pmid">33045718</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01396"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lan</surname><given-names>J.</given-names></name>
<name><surname>Ge</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Shan</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Shi</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id><pub-id pub-id-type="pmid">32225176</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01396"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Du</surname><given-names>Q.</given-names></name>
<name><surname>Guo</surname><given-names>B.</given-names></name>
<name><surname>Mu</surname><given-names>D.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays</article-title><source>J. Clin. Microbiol.</source><year>2020</year><volume>58</volume><fpage>e00375-20</fpage><pub-id pub-id-type="doi">10.1128/JCM.00375-20</pub-id><pub-id pub-id-type="pmid">32277023</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01396"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>M.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
</person-group><article-title>Distinct Variations of Antibody Secreting Cells and Memory B Cells during the Course of Kawasaki Disease</article-title><source>BMC Immunol.</source><year>2019</year><volume>20</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/s12865-019-0299-7</pub-id><pub-id pub-id-type="pmid">31159728</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01396"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berkowska</surname><given-names>M.A.</given-names></name>
<name><surname>Driessen</surname><given-names>G.J.A.</given-names></name>
<name><surname>Bikos</surname><given-names>V.</given-names></name>
<name><surname>Grosserichter-Wagener</surname><given-names>C.</given-names></name>
<name><surname>Stamatopoulos</surname><given-names>K.</given-names></name>
<name><surname>Cerutti</surname><given-names>A.</given-names></name>
<name><surname>He</surname><given-names>B.</given-names></name>
<name><surname>Biermann</surname><given-names>K.</given-names></name>
<name><surname>Lange</surname><given-names>J.F.</given-names></name>
<name><surname>van der Burg</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Human Memory B Cells Originate from Three Distinct Germinal Center-Dependent and -Independent Maturation Pathways</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>2150</fpage><lpage>2158</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-04-345579</pub-id><pub-id pub-id-type="pmid">21690558</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01396"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehdi</surname><given-names>F.</given-names></name>
<name><surname>Chattopadhyay</surname><given-names>S.</given-names></name>
<name><surname>Thiruvengadam</surname><given-names>R.</given-names></name>
<name><surname>Yadav</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>M.</given-names></name>
<name><surname>Sinha</surname><given-names>S.K.</given-names></name>
<name><surname>Goswami</surname><given-names>S.</given-names></name>
<name><surname>Kshetrapal</surname><given-names>P.</given-names></name>
<name><surname>Wadhwa</surname><given-names>N.</given-names></name>
<name><surname>Chandramouli Natchu</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>618097</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.618097</pub-id><pub-id pub-id-type="pmid">33552028</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01396"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walls</surname><given-names>A.C.</given-names></name>
<name><surname>Park</surname><given-names>Y.-J.</given-names></name>
<name><surname>Tortorici</surname><given-names>M.A.</given-names></name>
<name><surname>Wall</surname><given-names>A.</given-names></name>
<name><surname>McGuire</surname><given-names>A.T.</given-names></name>
<name><surname>Veesler</surname><given-names>D.</given-names></name>
</person-group><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>281</fpage><lpage>292.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmid">32155444</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01396"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khatri</surname><given-names>R.</given-names></name>
<name><surname>Parray</surname><given-names>H.A.</given-names></name>
<name><surname>Siddiqui</surname><given-names>G.</given-names></name>
<name><surname>Chiranjivi</surname><given-names>A.K.</given-names></name>
<name><surname>Raj</surname><given-names>S.</given-names></name>
<name><surname>Kaul</surname><given-names>R.</given-names></name>
<name><surname>Maithil</surname><given-names>V.</given-names></name>
<name><surname>Samal</surname><given-names>S.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
</person-group><article-title>Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants</article-title><source>Protein J.</source><year>2022</year><volume>41</volume><fpage>457</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1007/s10930-022-10073-6</pub-id><pub-id pub-id-type="pmid">36048314</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01396"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madhavan</surname><given-names>R.</given-names></name>
<name><surname>Paul</surname><given-names>J.S.</given-names></name>
<name><surname>Babji</surname><given-names>S.</given-names></name>
<name><surname>Thamizh</surname><given-names>I.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Khakha</surname><given-names>S.A.</given-names></name>
<name><surname>Rennie</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>K.</given-names></name>
<name><surname>Dhanapal</surname><given-names>P.</given-names></name>
<name><surname>Saravanan</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 Infections before, during, and after the Omicron Wave: A 2-Year Indian Community Cohort Study</article-title><source>Lancet Reg. Health Southeast Asia</source><year>2024</year><volume>28</volume><fpage>100470</fpage><pub-id pub-id-type="doi">10.1016/j.lansea.2024.100470</pub-id><pub-id pub-id-type="pmid">39263629</pub-id>
</element-citation></ref><ref id="B45-vaccines-12-01396"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Skountzou</surname><given-names>I.</given-names></name>
<name><surname>Satyabhama</surname><given-names>L.</given-names></name>
<name><surname>Stavropoulou</surname><given-names>A.</given-names></name>
<name><surname>Ashraf</surname><given-names>Z.</given-names></name>
<name><surname>Esser</surname><given-names>E.S.</given-names></name>
<name><surname>Vassilieva</surname><given-names>E.</given-names></name>
<name><surname>Koutsonanos</surname><given-names>D.</given-names></name>
<name><surname>Compans</surname><given-names>R.</given-names></name>
<name><surname>Jacob</surname><given-names>J.</given-names></name>
</person-group><article-title>Influenza Virus-Specific Neutralizing IgM Antibodies Persist for a Lifetime</article-title><source>Clin. Vaccine Immunol.</source><year>2014</year><volume>21</volume><fpage>1481</fpage><lpage>1489</lpage><pub-id pub-id-type="doi">10.1128/CVI.00374-14</pub-id><pub-id pub-id-type="pmid">25165027</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01396"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takemori</surname><given-names>T.</given-names></name>
<name><surname>Kaji</surname><given-names>T.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Shimoda</surname><given-names>M.</given-names></name>
<name><surname>Rajewsky</surname><given-names>K.</given-names></name>
</person-group><article-title>Generation of Memory B Cells inside and Outside Germinal Centers</article-title><source>Eur. J. Immunol.</source><year>2014</year><volume>44</volume><fpage>1258</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1002/eji.201343716</pub-id><pub-id pub-id-type="pmid">24610726</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01396"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shlomchik</surname><given-names>M.J.</given-names></name>
<name><surname>Weisel</surname><given-names>F.</given-names></name>
</person-group><article-title>Germinal Center Selection and the Development of Memory B and Plasma Cells</article-title><source>Immunol. Rev.</source><year>2012</year><volume>247</volume><fpage>52</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01124.x</pub-id><pub-id pub-id-type="pmid">22500831</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01396"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>E.L.</given-names></name>
<name><surname>Essigmann</surname><given-names>H.T.</given-names></name>
</person-group><article-title>Original Antigenic Sin: The Downside of Immunological Memory and Implications for COVID-19</article-title><source>mSphere</source><year>2021</year><volume>6</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/mSphere.00056-21</pub-id></element-citation></ref><ref id="B49-vaccines-12-01396"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sasikala</surname><given-names>M.</given-names></name>
<name><surname>Shashidhar</surname><given-names>J.</given-names></name>
<name><surname>Deepika</surname><given-names>G.</given-names></name>
<name><surname>Ravikanth</surname><given-names>V.</given-names></name>
<name><surname>Krishna</surname><given-names>V.V.</given-names></name>
<name><surname>Sadhana</surname><given-names>Y.</given-names></name>
<name><surname>Pragathi</surname><given-names>K.</given-names></name>
<name><surname>Reddy</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Immunological Memory and Neutralizing Activity to a Single Dose of COVID-19 Vaccine in Previously Infected Individuals</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>108</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.05.034</pub-id><pub-id pub-id-type="pmid">34022331</pub-id>
</element-citation></ref><ref id="B50-vaccines-12-01396"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamayoshi</surname><given-names>S.</given-names></name>
<name><surname>Yasuhara</surname><given-names>A.</given-names></name>
<name><surname>Ito</surname><given-names>M.</given-names></name>
<name><surname>Akasaka</surname><given-names>O.</given-names></name>
<name><surname>Nakamura</surname><given-names>M.</given-names></name>
<name><surname>Nakachi</surname><given-names>I.</given-names></name>
<name><surname>Koga</surname><given-names>M.</given-names></name>
<name><surname>Mitamura</surname><given-names>K.</given-names></name>
<name><surname>Yagi</surname><given-names>K.</given-names></name>
<name><surname>Maeda</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Antibody Titers against SARS-CoV-2 Decline, but Do Not Disappear for Several Months</article-title><source>EClinicalMedicine</source><year>2021</year><volume>32</volume><fpage>100734</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100734</pub-id><pub-id pub-id-type="pmid">33589882</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01396"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jo</surname><given-names>D.-H.</given-names></name>
<name><surname>Minn</surname><given-names>D.</given-names></name>
<name><surname>Lim</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>K.-D.</given-names></name>
<name><surname>Kang</surname><given-names>Y.-M.</given-names></name>
<name><surname>Choe</surname><given-names>K.-W.</given-names></name>
<name><surname>Kim</surname><given-names>K.-N.</given-names></name>
</person-group><article-title>Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1145</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9101145</pub-id><pub-id pub-id-type="pmid">34696253</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01396"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhary</surname><given-names>H.R.</given-names></name>
<name><surname>Parai</surname><given-names>D.</given-names></name>
<name><surname>Chandra Dash</surname><given-names>G.</given-names></name>
<name><surname>Kshatri</surname><given-names>J.S.</given-names></name>
<name><surname>Mishra</surname><given-names>N.</given-names></name>
<name><surname>Choudhary</surname><given-names>P.K.</given-names></name>
<name><surname>Pattnaik</surname><given-names>D.</given-names></name>
<name><surname>Panigrahi</surname><given-names>K.</given-names></name>
<name><surname>Behera</surname><given-names>S.</given-names></name>
<name><surname>Ranjan Sahoo</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines</article-title><source>Front. Med.</source><year>2021</year><volume>8</volume><elocation-id>778129</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2021.778129</pub-id></element-citation></ref><ref id="B53-vaccines-12-01396"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goel</surname><given-names>R.R.</given-names></name>
<name><surname>Painter</surname><given-names>M.M.</given-names></name>
<name><surname>Apostolidis</surname><given-names>S.A.</given-names></name>
<name><surname>Mathew</surname><given-names>D.</given-names></name>
<name><surname>Meng</surname><given-names>W.</given-names></name>
<name><surname>Rosenfeld</surname><given-names>A.M.</given-names></name>
<name><surname>Lundgreen</surname><given-names>K.A.</given-names></name>
<name><surname>Reynaldi</surname><given-names>A.</given-names></name>
<name><surname>Khoury</surname><given-names>D.S.</given-names></name>
<name><surname>Pattekar</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>mRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>abm0829</fpage><pub-id pub-id-type="doi">10.1126/science.abm0829</pub-id><pub-id pub-id-type="pmid">34648302</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01396"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaku</surname><given-names>C.I.</given-names></name>
<name><surname>Bergeron</surname><given-names>A.J.</given-names></name>
<name><surname>Ahlm</surname><given-names>C.</given-names></name>
<name><surname>Normark</surname><given-names>J.</given-names></name>
<name><surname>Sakharkar</surname><given-names>M.</given-names></name>
<name><surname>Forsell</surname><given-names>M.N.E.</given-names></name>
<name><surname>Walker</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Recall of Preexisting Cross-Reactive B Cell Memory after Omicron BA.1 Breakthrough Infection</article-title><source>Sci. Immunol.</source><year>2022</year><volume>7</volume><fpage>eabq3511</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abq3511</pub-id><pub-id pub-id-type="pmid">35549299</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01396"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Muecksch</surname><given-names>F.</given-names></name>
<name><surname>Raspe</surname><given-names>R.</given-names></name>
<name><surname>Johannsen</surname><given-names>F.</given-names></name>
<name><surname>Turroja</surname><given-names>M.</given-names></name>
<name><surname>Canis</surname><given-names>M.</given-names></name>
<name><surname>ElTanbouly</surname><given-names>M.A.</given-names></name>
<name><surname>Santos</surname><given-names>G.S.S.</given-names></name>
<name><surname>Johnson</surname><given-names>B.</given-names></name>
<name><surname>Baharani</surname><given-names>V.A.</given-names></name>
<etal/>
</person-group><article-title>Memory B Cell Development Elicited by mRNA Booster Vaccinations in the Elderly</article-title><source>J. Exp. Med.</source><year>2023</year><volume>220</volume><fpage>e20230668</fpage><pub-id pub-id-type="doi">10.1084/jem.20230668</pub-id><pub-id pub-id-type="pmid">37368240</pub-id>
</element-citation></ref><ref id="B56-vaccines-12-01396"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morales-N&#x000fa;&#x000f1;ez</surname><given-names>J.J.</given-names></name>
<name><surname>Garc&#x000ed;a-Chagoll&#x000e1;n</surname><given-names>M.</given-names></name>
<name><surname>Mu&#x000f1;oz-Valle</surname><given-names>J.F.</given-names></name>
<name><surname>D&#x000ed;az-P&#x000e9;rez</surname><given-names>S.A.</given-names></name>
<name><surname>Torres-Hern&#x000e1;ndez</surname><given-names>P.C.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Reyes</surname><given-names>S.C.</given-names></name>
<name><surname>Santoscoy-Ascencio</surname><given-names>G.</given-names></name>
<name><surname>Sierra Garc&#x000ed;a de Quevedo</surname><given-names>J.J.</given-names></name>
<name><surname>Hern&#x000e1;ndez-Bello</surname><given-names>J.</given-names></name>
</person-group><article-title>Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19&#x02014;A Prospective Cohort Study</article-title><source>J. Inflamm. Res.</source><year>2022</year><volume>15</volume><fpage>4449</fpage><lpage>4466</lpage><pub-id pub-id-type="doi">10.2147/JIR.S374304</pub-id><pub-id pub-id-type="pmid">35958186</pub-id>
</element-citation></ref><ref id="B57-vaccines-12-01396"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terreri</surname><given-names>S.</given-names></name>
<name><surname>Piano Mortari</surname><given-names>E.</given-names></name>
<name><surname>Vinci</surname><given-names>M.R.</given-names></name>
<name><surname>Russo</surname><given-names>C.</given-names></name>
<name><surname>Alteri</surname><given-names>C.</given-names></name>
<name><surname>Albano</surname><given-names>C.</given-names></name>
<name><surname>Colavita</surname><given-names>F.</given-names></name>
<name><surname>Gramigna</surname><given-names>G.</given-names></name>
<name><surname>Agrati</surname><given-names>C.</given-names></name>
<name><surname>Linardos</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Persistent B Cell Memory after SARS-CoV-2 Vaccination Is Functional during Breakthrough Infections</article-title><source>Cell Host Microbe</source><year>2022</year><volume>30</volume><fpage>400</fpage><lpage>408.e4</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2022.01.003</pub-id><pub-id pub-id-type="pmid">35134333</pub-id>
</element-citation></ref><ref id="B58-vaccines-12-01396"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geropeppa</surname><given-names>M.</given-names></name>
<name><surname>Papadatou</surname><given-names>I.</given-names></name>
<name><surname>Sarantis</surname><given-names>P.</given-names></name>
<name><surname>Tzanoudaki</surname><given-names>M.</given-names></name>
<name><surname>Ntanasis-Stathopoulos</surname><given-names>I.</given-names></name>
<name><surname>Bagratuni</surname><given-names>T.</given-names></name>
<name><surname>Terpos</surname><given-names>E.</given-names></name>
<name><surname>Spoulou</surname><given-names>V.</given-names></name>
</person-group><article-title>Receptor-Binding-Domain-Specific B Cell Responses Induced by mRNA Immunization against SARS-CoV-2</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1148</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11071148</pub-id><pub-id pub-id-type="pmid">37514964</pub-id>
</element-citation></ref><ref id="B59-vaccines-12-01396"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bus&#x000e0;</surname><given-names>R.</given-names></name>
<name><surname>Miele</surname><given-names>M.</given-names></name>
<name><surname>Sorrentino</surname><given-names>M.C.</given-names></name>
<name><surname>Amico</surname><given-names>G.</given-names></name>
<name><surname>Timoneri</surname><given-names>F.</given-names></name>
<name><surname>Miceli</surname><given-names>V.</given-names></name>
<name><surname>Di Bella</surname><given-names>M.</given-names></name>
<name><surname>Russelli</surname><given-names>G.</given-names></name>
<name><surname>Gallo</surname><given-names>A.</given-names></name>
<name><surname>Zito</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Long-Term Effectiveness of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine on B Cell Compartment: Efficient Recall of SARS-CoV-2-Specific Memory B Cells</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>15046</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232315046</pub-id><pub-id pub-id-type="pmid">36499373</pub-id>
</element-citation></ref><ref id="B60-vaccines-12-01396"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brewer</surname><given-names>R.C.</given-names></name>
<name><surname>Ramadoss</surname><given-names>N.S.</given-names></name>
<name><surname>Lahey</surname><given-names>L.J.</given-names></name>
<name><surname>Jahanbani</surname><given-names>S.</given-names></name>
<name><surname>Robinson</surname><given-names>W.H.</given-names></name>
<name><surname>Lanz</surname><given-names>T.V.</given-names></name>
</person-group><article-title>BNT162b2 Vaccine Induces Divergent B Cell Responses to SARS-CoV-2 S1 and S2</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01088-9</pub-id><pub-id pub-id-type="pmid">34848871</pub-id>
</element-citation></ref><ref id="B61-vaccines-12-01396"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mise-Omata</surname><given-names>S.</given-names></name>
<name><surname>Ikeda</surname><given-names>M.</given-names></name>
<name><surname>Takeshita</surname><given-names>M.</given-names></name>
<name><surname>Uwamino</surname><given-names>Y.</given-names></name>
<name><surname>Wakui</surname><given-names>M.</given-names></name>
<name><surname>Arai</surname><given-names>T.</given-names></name>
<name><surname>Yoshifuji</surname><given-names>A.</given-names></name>
<name><surname>Murano</surname><given-names>K.</given-names></name>
<name><surname>Siomi</surname><given-names>H.</given-names></name>
<name><surname>Nakagawara</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant</article-title><source>J. Immunol.</source><year>2022</year><volume>209</volume><fpage>2104</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200525</pub-id><pub-id pub-id-type="pmid">36426984</pub-id>
</element-citation></ref><ref id="B62-vaccines-12-01396"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weisel</surname><given-names>N.M.</given-names></name>
<name><surname>Joachim</surname><given-names>S.M.</given-names></name>
<name><surname>Smita</surname><given-names>S.</given-names></name>
<name><surname>Callahan</surname><given-names>D.</given-names></name>
<name><surname>Elsner</surname><given-names>R.A.</given-names></name>
<name><surname>Conter</surname><given-names>L.J.</given-names></name>
<name><surname>Chikina</surname><given-names>M.</given-names></name>
<name><surname>Farber</surname><given-names>D.L.</given-names></name>
<name><surname>Weisel</surname><given-names>F.J.</given-names></name>
<name><surname>Shlomchik</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Surface Phenotypes of Naive and Memory B Cells in Mouse and Human Tissues</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01078-x</pub-id><pub-id pub-id-type="pmid">34937918</pub-id>
</element-citation></ref><ref id="B63-vaccines-12-01396"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grimsholm</surname><given-names>O.</given-names></name>
</person-group><article-title>CD27 on Human Memory B Cells-More than Just a Surface Marker</article-title><source>Clin. Exp. Immunol.</source><year>2023</year><volume>213</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1093/cei/uxac114</pub-id><pub-id pub-id-type="pmid">36508329</pub-id>
</element-citation></ref><ref id="B64-vaccines-12-01396"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
</person-group><article-title>CD27 Is Not an Ideal Marker for Human Memory B Cells and Can Be Modulated by IL-21 upon Stimulated by Anti-CD40</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>23742</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-75636-2</pub-id><pub-id pub-id-type="pmid">39390111</pub-id>
</element-citation></ref><ref id="B65-vaccines-12-01396"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bednarski</surname><given-names>E.</given-names></name>
<name><surname>Del Rio Estrada</surname><given-names>P.M.</given-names></name>
<name><surname>DaSilva</surname><given-names>J.</given-names></name>
<name><surname>Boukadida</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Luna-Villalobos</surname><given-names>Y.A.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Rangel</surname><given-names>X.</given-names></name>
<name><surname>Pit&#x000e9;n-Isidro</surname><given-names>E.</given-names></name>
<name><surname>Luna-Garc&#x000ed;a</surname><given-names>E.</given-names></name>
<name><surname>D&#x000ed;az Rivera</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population</article-title><source>mBio</source><year>2022</year><volume>13</volume><fpage>e00840-22</fpage><pub-id pub-id-type="doi">10.1128/mbio.00840-22</pub-id><pub-id pub-id-type="pmid">35735743</pub-id>
</element-citation></ref><ref id="B66-vaccines-12-01396"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Mateus</surname><given-names>J.</given-names></name>
<name><surname>Coelho</surname><given-names>C.H.</given-names></name>
<name><surname>Dan</surname><given-names>J.M.</given-names></name>
<name><surname>Moderbacher</surname><given-names>C.R.</given-names></name>
<name><surname>G&#x000e1;lvez</surname><given-names>R.I.</given-names></name>
<name><surname>Cortes</surname><given-names>F.H.</given-names></name>
<name><surname>Grifoni</surname><given-names>A.</given-names></name>
<name><surname>Tarke</surname><given-names>A.</given-names></name>
<name><surname>Chang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Humoral and Cellular Immune Memory to Four COVID-19 Vaccines</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>2434</fpage><lpage>2451.e17</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.05.022</pub-id><pub-id pub-id-type="pmid">35764089</pub-id>
</element-citation></ref><ref id="B67-vaccines-12-01396"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fryer</surname><given-names>H.A.</given-names></name>
<name><surname>Hartley</surname><given-names>G.E.</given-names></name>
<name><surname>Edwards</surname><given-names>E.S.J.</given-names></name>
<name><surname>O&#x02019;Hehir</surname><given-names>R.E.</given-names></name>
<name><surname>van Zelm</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Humoral Immunity and B-Cell Memory in Response to SARS-CoV-2 Infection and Vaccination</article-title><source>Biochem. Soc. Trans.</source><year>2022</year><volume>50</volume><fpage>1643</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1042/BST20220415</pub-id><pub-id pub-id-type="pmid">36421662</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01396-f001"><label>Figure 1</label><caption><p>IgG antibody levels against SARS-CoV-2 receptor-binding domain (RBD) of spike protein among unvaccinated and vaccinated participants.</p></caption><graphic xlink:href="vaccines-12-01396-g001" position="float"/></fig><fig position="float" id="vaccines-12-01396-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>) Representative flow cytometry gating strategy for SARS-CoV-2 RBD-specific memory B cells (CD3<sup>&#x02212;</sup>, CD19<sup>+</sup>, CD20<sup>+</sup>, IgD<sup>&#x02212;</sup>, CD27<sup>+</sup>, RBD<sup>+</sup>). (<bold>B</bold>) Graphical representation comparing the percentage of RBD-specific memory B cells in vaccinated and unvaccinated participants [outliers removed using iterative Grubb&#x02019;s test, alpha = 0.01].</p></caption><graphic xlink:href="vaccines-12-01396-g002" position="float"/></fig><fig position="float" id="vaccines-12-01396-f003"><label>Figure 3</label><caption><p>(<bold>A</bold>) Schematic ELISPOT assay plate map (created using BioRender). (<bold>B</bold>) Representative plate image showing the total and RBD-specific antibody-secreting cells (ASCs) among the cells collected from an unvaccinated and a vaccinated individual.</p></caption><graphic xlink:href="vaccines-12-01396-g003" position="float"/></fig><fig position="float" id="vaccines-12-01396-f004"><label>Figure 4</label><caption><p>Fraction of the RBD-specific ASCs (IgA, IgG, and IgM) among vaccinated versus unvaccinated individuals [outliers removed using iterative Grubb&#x02019;s test, alpha = 0.01].</p></caption><graphic xlink:href="vaccines-12-01396-g004" position="float"/></fig><fig position="float" id="vaccines-12-01396-f005"><label>Figure 5</label><caption><p>Fraction of the RBD-specific ASCs (IgA, IgG, and IgM) to depict temporal changes (for participants vaccinated more than 6 months prior to sample collection): (<bold>A</bold>) among Corbevax-vaccinated versus unvaccinated individuals, (<bold>B</bold>) among Covaxin-vaccinated versus unvaccinated individuals, (<bold>C</bold>) among Covishield-vaccinated versus unvaccinated individuals, and (<bold>D</bold>) among Sputnik-Light-vaccinated versus unvaccinated individuals [Mann&#x02013;Whitney U test; * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01; outliers were removed using iterative Grubb&#x02019;s test, alpha = 0.01].</p></caption><graphic xlink:href="vaccines-12-01396-g005a" position="float"/><graphic xlink:href="vaccines-12-01396-g005b" position="float"/></fig><fig position="float" id="vaccines-12-01396-f006"><label>Figure 6</label><caption><p>Gender-disaggregated analysis of immune response and memory B cell response. (<bold>A</bold>) IgG antibody levels against SARS-CoV-2 spike RBD compared between male and female participants. (<bold>B</bold>) Percentage of RBD-specific memory B cells in the peripheral circulation of male and female participants segregated based on the vaccine given. (<bold>C</bold>) Percentage of RBD-specific IgA, IgG, and IgM spot-forming units in unvaccinated and vaccinated males and females.</p></caption><graphic xlink:href="vaccines-12-01396-g006" position="float"/></fig><table-wrap position="float" id="vaccines-12-01396-t001"><object-id pub-id-type="pii">vaccines-12-01396-t001_Table 1</object-id><label>Table 1</label><caption><p>Participant details (A) and demography (B).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="7" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">(A)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sr. No.</th><th colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Status of Vaccination</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Number</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Unvaccinated</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">35</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccinated (Corbevax)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">34</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccinated (Covaxin)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">33</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccinated (Covishield)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccinated (Sputnik Light)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">29</td></tr><tr><td colspan="7" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>(B)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Unvaccinated</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Corbevax</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Covishield</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Covaxin</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sputnik Light</bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (18&#x02013;55)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 (20&#x02013;46)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (19&#x02013;53)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 (21&#x02013;54)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39 (20&#x02013;59)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Months since vaccination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Range</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (3&#x02013;8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (3&#x02013;15)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (3&#x02013;15)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (6&#x02013;11)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01396-t002"><object-id pub-id-type="pii">vaccines-12-01396-t002_Table 2</object-id><label>Table 2</label><caption><p>Molecular markers used for the memory B cell estimation in the peripheral circulation of the study participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SN.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Molecular Marker</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fluorophore</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Make and Catalogue Number</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Fixable viability dye</td><td align="center" valign="middle" rowspan="1" colspan="1">Violet Dye</td><td align="center" valign="middle" rowspan="1" colspan="1">Invitrogen, Waltham, MA, USA #L34964</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">CD3</td><td align="center" valign="middle" rowspan="1" colspan="1">PerCP</td><td align="center" valign="middle" rowspan="1" colspan="1">BioLegend, San Diego, CA, USA #344814</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">CD19</td><td align="center" valign="middle" rowspan="1" colspan="1">PE</td><td align="center" valign="middle" rowspan="1" colspan="1">BioLegend, San Diego, CA, USA #302208</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">CD20</td><td align="center" valign="middle" rowspan="1" colspan="1">APC</td><td align="center" valign="middle" rowspan="1" colspan="1">BioLegend, San Diego, CA, USA #302310</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">CD27</td><td align="center" valign="middle" rowspan="1" colspan="1">PE-Cy7</td><td align="center" valign="middle" rowspan="1" colspan="1">BioLegend, San Diego, CA, USA #356412</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APC-Cy7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioLegend, San Diego, CA, USA #348218</td></tr></tbody></table></table-wrap></floats-group></article>